The Efficacy & Safety of HLX208 in Adult Langerhans Cell Histiocytosis

See also
Status	Clinical Trial	Phase
Completed	`NCT03270020` - Denosumab for the Treatment of Adult LCH	Phase 2
Recruiting	`NCT05997602` - To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH	Phase 2
Recruiting	`NCT05915208` - Histiocytic Disorder Follow-up Study
Completed	`NCT03096782` - Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma	Phase 2
Recruiting	`NCT04120519` - Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis	Phase 2
Not yet recruiting	`NCT05477446` - Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With R/R Langerhans Cell Histiocytosis	Phase 1
Recruiting	`NCT04121819` - AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis	Phase 2
Recruiting	`NCT05284942` - Central China Rosai-Dorfman Disease Registry	Phase 4
Active, not recruiting	`NCT03220035` - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Completed	`NCT02608619` - Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement
Completed	`NCT01395004` - A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis	Phase 2
Recruiting	`NCT02205762` - LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis	Phase 2/Phase 3
Active, not recruiting	`NCT02425904` - Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders	Phase 2
Recruiting	`NCT02670707` - Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)	Phase 3
Completed	`NCT02665546` - Evaluation of Exercise Capacity and Exercise Limitation in Patients With Pulmonary Langerhans Cell Histiocytosis
Recruiting	`NCT04627090` - LCH in Adults: a Collaborative, Prospective-retrospective, Observational Study
Recruiting	`NCT03585686` - A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation	Phase 2
Recruiting	`NCT03155620` - Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	Phase 2
Recruiting	`NCT04773366` - A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol	Phase 3
Completed	`NCT02389400` - Methotrexate and Cytosine in Adult Langerhans Cell Histiocytosis	Phase 2

NCT number	NCT05092815
Study type	Interventional
Source	Shanghai Henlius Biotech
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	December 6, 2021
Completion date	October 30, 2024

The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms